Telix   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Melbourne Australia (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2019
NCT03762759
First Marketed Drug
2021
68ga-psma
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TELIX | Telix International Pty Ltd | Telix Pharmaceutical

Active Ingredients

Marketed Drugs (1)

Key: Telix (0) Acquired (1)

68ga-psma (2021)

Drugs in Phase 3 Trials (3)

Key: Telix (1) Acquired (2)

177lu-dota-tlx591 (3 trials)

68ga-psma (1 trial)

fluorocholine (1 trial)

Drugs in Phase 2 Trials (2)

89zr-tlx250 (1 trial)

Fluciclovine (Axumin) (1 trial)

Drugs in Phase 1 Trials (2)

64cu-dota-tlx592 (1 trial)

girentuximab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 7